title: Improving effect of carteolol on bodyweight and carbohydrate and lipid metabolic responses in the OLETF rat.
abstract: 1. Carteolol, a non-selective beta-blocker with intrinsic sympathomimetic activity, admixed in a pellet diet was administered to Otsuka Long-Evans Tokushima Fatty (OLETF) rats, an animal model of spontaneous non-insulin-dependent diabetes mellitus with mild obesity. A high dose of carteolol (0.02%) suppressed bodyweight gain without affecting food and water consumption until the appearance of glycosuria. Carteolol tended to reduce the cumulative incidence of glycosuria at 26 weeks after the beginning of administration (55, 17 and 25% in control rats, and in rats fed a low (0.002%) and high dose of carteolol, respectively). 2. At the 26th week of administration, the high dose of carteolol decreased visceral fat weight, such as that of retroperitoneal and epididymal adipose tissue, whereas the liver and the kidney were not affected. 3. Although plasma glucose and triglyceride levels in non-fasted rats were elevated with age, carteolol tended to delay the increases in those parameters. Carteolol suppressed the increase in plasma glucose levels, which indicate the diabetic pattern, in a 25th week oral glucose tolerance test. 4. These findings indicate that carteolol induces improvements in bodyweight and carbohydrate and lipid metabolism in an obese condition. Consequently, carteolol may be useful for the treatment of hypertension with obesity in order to prevent cardiovascular events.
authors.affiliation: Department of Pharmacology and Experimental Therapeutics, Tokushima Research Institute, Otsuka Pharmaceutical Co. Ltd, Japan. y_saitoh@research.otsuka.co.jp
authors.forename: Y
authors.initials: Y
authors.lastname: Saitoh
authors.forename: T
authors.initials: T
authors.lastname: Tani
authors.forename: Y
authors.initials: Y
authors.lastname: Asahi
authors.forename: Z
authors.initials: Z
authors.lastname: Man
authors.forename: K
authors.initials: K
authors.lastname: Kawano
authors.forename: H
authors.initials: H
authors.lastname: Ikunaga
mesh_terms: D000273:Adipose Tissue / Q000187:drug effects; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism*; D001835:Body Weight / Q000187:drug effects*; D002354:Carteolol / Q000494:pharmacology; D002784:Cholesterol / Q000097:blood; D003921:Diabetes Mellitus, Experimental / Q000097:blood* / Q000503:physiopathology; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000503:physiopathology; D006029:Glycosuria / Q000517:prevention & control; D007328:Insulin / Q000097:blood; D008055:Lipids / Q000097:blood*; D008297:Male; D051381:Rats; D014280:Triglycerides / Q000097:blood
chemical_list: D000319:Adrenergic beta-Antagonists; D001786:Blood Glucose; D007328:Insulin; D008055:Lipids; D014280:Triglycerides; D002354:Carteolol; D002784:Cholesterol